Beijing, China, November 01, 2023 - Gan & Lee Pharmaceuticals (Stock code: 603087. SH) announced that it has recently achieved success in the Kazakh government's tender project as a Marketing Authorization Holder (MAH) for both insulin aspart injection (Rapilin™) and insulin pen (GanleePen™) products required by the Kazakh public market in the coming year.

After a rigorous bidding process and thorough technical evaluation of the products, Gan & Lee emerged as the winner, demonstrating outstanding product quality and a competitive pricing strategy. This achievement not only solidified the company's firm pace within the "Belt and Road" Initiative but also provided a significant impetus for Gan & Lee's international market expansion, enhancing the brand's global presence.

Last August, Gan & Lee's insulin aspart injection was approved in Kazakhstan. This was the company's first overseas approval as a MAH, marking an important breakthrough for the product to go international under the Gan & Lee brand. In May, Gan & Lee's insulin pen was also approved in Kazakhstan, further making a complete product portfolio for diabetes treatment.

As a company driven by innovation, Gan & Lee is always committed to the development of high-quality and high-performance pharmaceutical products to provide better scientific solutions for patients worldwide and make a sustainable contribution to the improvement of human health.

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.